Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Shanghai MicroPort MedBot (Group) Co., Ltd. (2252.HK)
Shanghai, CN
Shanghai MicroPort MedBot (Group) Co., Ltd. focuses on the comprehensive research, development, design, production, and distribution of surgical robotic systems, catering to markets in China and Europe. Their innovative product range features Toumai, a versatile laparoscopic surgical robot employed in urologic, gynecologic, thoracic, and general surgeries. They also provide DFVision, a 3D electronic laparoscope designed to improve visualization during abdominal, thoracic, and pelvic operations. For orthopedic procedures, the Honghu robot aids in knee and hip joint replacements, while the R-One system is specifically engineered for vascular interventions like coronary angioplasty. The iSR'obot, known as the Mona Lisa robotic system, specializes in transperineal prostate biopsies. Additionally, the company's offerings extend to specialized robots for spinal procedures, trans-bronchial diagnosis and treatment, TAVR (Transcatheter Aortic Valve Replacement), and automated needle-targeting systems for precise percutaneous lung biopsies and nephrolithotomy. Founded in 2014 and headquartered in Shanghai, China, the company functions as a subsidiary of MicroPort Scientific Corporation.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.39% | -7.85% | -18.31% | -9.31% | +12.62% | +4.28% | +60.79% | +38.32% | -44.67% | -44.67% | -44.67% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 5 | 0 |
| Hold | 1 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+114.2% ★ Q4'25: +558.7% (vs Q4'23)
-
EPS growth Medical - Devices: +28.5%+63.6% ★ Q4'25: +74.0% (vs Q4'23)
-
FCF margin FCF growth · Medical - Devices: +30.9%-20.3% Q4'25: +21.6% (vs Q4'23)
-
EBIT margin Medical - Devices: +6.2%-31.0% Q4'25: -17.2% (vs Q4'23)
-
ROIC Medical - Devices: +3.3%-91.9% Q4'25: -138.7% (vs Q4'23)
-
Share dilution Medical - Devices: 0.0%+5.7% Q4'25: +7.6% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-4.40× Q4'25: -4.01× (vs Q4'23)
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 7 Rev. Ana. 4 EPS Ana. |
Dec 2027 7 Rev. Ana. 4 EPS Ana. |
Dec 2028 6 Rev. Ana. 6 EPS Ana. |
Dec 2029 5 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
21.60M
est: 29.99M (-28.0%)
|
104.59M
est: 145.32M (-28.0%)
|
257.25M
est: 262.34M (-1.9%)
|
551.07M
est: 553.14M (-0.4%)
|
1.17B
1.01B – 1.42B
+112.1% YoY
|
1.84B
1.58B – 2.33B
+56.4% YoY
|
2.67B
2.30B – 3.33B
+45.5% YoY
|
3.09B
2.66B – 3.85B
+15.6% YoY
|
| EBITDA |
-1.05B
est: -17.99M (-5,760.0%)
|
-893.36M
est: -121.36M (-636.1%)
|
-413.34M
est: -219.09M (-88.7%)
|
-96.84M
est: -461.95M (+79.0%)
|
-979.80M
-1.19B – -846.43M
-112.1% YoY
|
-1.53B
-1.95B – -1.32B
-56.4% YoY
|
-2.23B
-2.78B – -1.92B
-45.5% YoY
|
-2.58B
-3.22B – -2.22B
-15.6% YoY
|
| EBIT |
-1.10B
est: -17.99M (-5,996.0%)
|
-1.01B
est: -125.28M (-702.3%)
|
-474.38M
est: -226.15M (-109.8%)
|
-171.00M
est: -476.84M (+64.1%)
|
-1.01B
-1.22B – -873.70M
-112.1% YoY
|
-1.58B
-2.01B – -1.36B
-56.4% YoY
|
-2.30B
-2.87B – -1.98B
-45.5% YoY
|
-2.66B
-3.32B – -2.29B
-15.6% YoY
|
| Net Income |
-1.14B
est: -848.37M (-34.4%)
|
-1.01B
est: -697.95M (-45.0%)
|
-642.41M
est: -436.58M (-47.1%)
|
-249.66M
est: -246.52M (-1.3%)
|
67.99M
59.53M – 87.43M
+127.6% YoY
|
292.80M
268.06M – 317.53M
+330.6% YoY
|
473.51M
263.17M – 1.25B
+61.7% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
354.51M
est: 773.62M (-54.2%)
|
364.79M
est: 3.73B (-90.2%)
|
263.22M
est: 6.74B (-96.1%)
|
249.25M
est: 14.21B (-98.2%)
|
30.13B
26.03B – 36.50B
+112.1% YoY
|
47.14B
40.49B – 59.90B
+56.4% YoY
|
68.57B
59.03B – 85.53B
+45.5% YoY
|
79.28B
68.25B – 98.89B
+15.6% YoY
|
| EPS |
-1.19
est: -0.79 (-49.9%)
|
-1.06
est: -0.73 (-45.6%)
|
-0.66
est: -0.52 (-27.0%)
|
-0.24
est: -0.24 (+0.3%)
|
0.07
0.06 – 0.09
+129.9% YoY
|
0.29
0.26 – 0.31
+298.5% YoY
|
0.53
0.26 – 1.22
+84.5% YoY
|
—
— – —
-100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Global X - Robotics & Artificial Intelligence UCITS ETF BOTG.L | 1.02% | 258.4K | 0.50% |
| 2 | Global X - Robotics & Artificial Intelligence UCITS ETF BOTZ.L | 1.02% | 1.59M | 0.50% |
| 3 | iShares MSCI China Small-Cap ETF ECNS | 0.80% | 521.9K | 0.59% |
| 4 | Global X - Robotics & Artificial Intelligence ETF BOTZ | 0.72% | 24.79M | 0.68% |
| 5 | Matthews Emerging Markets Discovery Active ETF MEMS MEMS | 0.34% | 75.9K | 0.99% |
| 6 | iShares Healthcare Innovation UCITS ETF HEAL.L | 0.17% | 1.91M | 0.40% |
| 7 | UBS Solactive China Technology UCITS ETF USD acc CQQQ.SW | 0.16% | 583.4K | 0.47% |
| 8 | UBS Solactive China Technology UCITS ETF hEUR acc CITE.MI | 0.16% | 580.1K | 0.50% |
| 9 | WisdomTree China ex-State-Owned Enterprises Fund CXSE | 0.12% | 579.8K | 0.32% |
| 10 | iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L | 0.11% | 82.3K | 0.74% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chao He | President & Executive Director | 2M | — |
| Yu Liu | Vice President, Chief Commercial Officer & Executive Director | 2M | male |
| Siu Lam Yeung | Company Secretary | — | female |
| Xiaoyu Cui | Financial Controller | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2252.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
